LC
REGN icon

Lindbrook Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Lindbrook Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$746K Buy
1,177
+26
+2% +$17.9K 0.07% 166
2024
Q4 		$820K Buy
1,151
+6
+0.5% +$5.04K 0.07% 156
2024
Q3 		$1.2M Sell
1,145
-14
-1% -$15.6K 0.11% 125
2024
Q2 		$1.22M Buy
1,159
+40
+4% +$38.8K 0.11% 114
2024
Q1 		$1.08M Buy
1,119
+15
+1% +$14.3K 0.1% 128
2023
Q4 		$970K Buy
1,104
+74
+7% +$60.9K 0.1% 127
2023
Q3 		$848K Buy
1,030
+37
+4% +$29.1K 0.09% 121
2023
Q2 		$714K Sell
993
-48
-5% -$37K 0.08% 149
2023
Q1 		$855K Buy
1,041
+79
+8% +$59.6K 0.1% 124
2022
Q4 		$694K Buy
962
+34
+4% +$25.1K 0.09% 147
2022
Q3 		$639K Buy
928
+34
+4% +$21.4K 0.11% 112
2022
Q2 		$528K Sell
894
-17
-2% -$11.1K 0.09% 144
2022
Q1 		$636K Buy
911
+13
+1% +$8.22K 0.1% 133
2021
Q4 		$567K Sell
898
-1
-0.1% -$615 0.09% 144
2021
Q3 		$544K Buy
899
+8
+0.9% +$4.97K 0.14% 61
2021
Q2 		$498K Buy
891
+51
+6% +$25.8K 0.11% 80
2021
Q1 		$397K Sell
840
-39
-4% -$19K 0.09% 94
2020
Q4 		$425K Buy
879
+51
+6% +$27.5K 0.1% 79
2020
Q3 		$463K Sell
828
-45
-5% -$27.3K 0.13% 65
2020
Q2 		$544K Buy
873
+11
+1% +$6.24K 0.16% 48
2020
Q1 		$421K Sell
862
-3
-0.3% -$1.24K 0.16% 51
2019
Q4 		$325K Buy
865
+5
+0.6% +$1.68K 0.11% 88
2019
Q3 		$239K Buy
860
+68
+9% +$20.1K 0.09% 109
2019
Q2 		$247K Sell
792
-48
-6% -$16K 0.1% 106
2019
Q1 		$344K Hold
840
– – 0.14% 75
2018
Q4 		$313K Buy
+840
New +$307K 0.15% 65

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lindbrook Capital's REGN Position: Q1 2025 in Review

Lindbrook Capital increased its Regeneron Pharmaceuticals (REGN) stake by 2.3% in Q1 2025, buying an estimated $17.9K and bringing the position to 1,177 shares worth $746K. The position accounts for 0.07% of the portfolio, ranked #166.

Lindbrook Capital first reported a position in REGN in Q4 2018 and has held it in 26 quarters since. The position peaked at $1.22M in Q2 2024. 1,291 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Lindbrook Capital held 1,177 shares of Regeneron Pharmaceuticals worth $746K as of Q1 2025.
  • Lindbrook Capital bought 26 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $17.9K.
  • Regeneron Pharmaceuticals made up 0.07% of Lindbrook Capital's portfolio in Q1 2025, its #166 holding.
  • Lindbrook Capital first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 26 quarters since.
  • Lindbrook Capital's Regeneron Pharmaceuticals position peaked at $1.22M in Q2 2024.
  • 1,291 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.